Empagliflozin outcome trial in patients with chronic heart failure with reduced ejection fraction
By Marr - /
1 Comments
— Stefan Anker, MD, says it should be "the new paradigm" for treatment of patients with LVEF 50%
Some regional and racial differences in efficacy were noted. February 20, Key Record Dates. See more VermaSubodh Verma. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Pierchala, M. Racial groups are not homogeneous and varied meaningfully with respect to baseline characteristics, and it is likely that unmeasured confounders may have contributed to the differences that we observed.
Publication types
During these visits, the doctors collect information about the participant's health. By Todd Neale. The study was monitored by an independent data safety and monitoring committee. Drug: Empagliflozin Drug: Placebo.
Matching Exact phrase Include all of these words See more some of these words. Supplementary data. Search for terms. The trial was designed to enroll patients receiving standard-of-care therapy for HFpEF. References 1. Accepted : 10 September When outpatient HF events were included in the extended composite endpoint, the magnitude of the effect of empagliflozin was amplified in Europe where outpatient events were most numerous the hazard ratio declined from 0.
Specialty Menu Navigation
Article Google Scholar For permissions, please email: journals. More Information. Cocca-Spofford, R. Occurrence of all-cause hospitalisation first and recurrent. Heart Failure. Open in new tab.
.png "empagliflozin outcome trial in patients with chronic heart failure with reduced ejection fraction")
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. An AstraZeneca research grant to M.
Video Guide
Keynote Please click for source Heart Failure with Reduced Ejection Fraction (G. MICHAEL FELKER, MD) please click for source outcome trial in patients with chronic heart failure with reduced ejection fraction - excellent The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.Actual Study Completion Date :. Juni, R. These regional differences were driven by differences in the incidence of HF hospitalization, since there were no meaningful differences among regions in the incidence of cardiovascular death Asia 7. Extended data. All primary and secondary efficacy endpoints https://digitales.com.au/blog/wp-content/review/anti-diabetic/can-losartan-make-your-blood-pressure-too-low.php evaluated using the modified intention-to-treat dataset, which included all randomized patients who received at least one dose of study medication and had at least one evaluable endpoint. Ferkl s.
Eligibility Criteria. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. Funding was obtained by M. Prerov, Czechia, Nemocnice Trebic p. Am Heart J ; : 66 — Greg Laub is the Senior Director of Video and currently leads the video and outcom production teams. Interventional Clinical Trial. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Before administration of the first dose of dapagliflozin or placebo, patients underwent a physical examination, trial-related laboratory assessments, completion of the KCCQ and a 6MWT. Carolyn S.
